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Abstract
The rising prevalence of overweight and obesity in the world has been described as a
global pandemic, with marked variations across countries in the levels and trends in
overweight and obesity with distinct regional patterns. Concern about the health risks
associated with rising obesity has become nearly universal. In this chapter, a systematic
review that was conducted in four databases (Web of Science,  MEDLINE, Scopus,
CINAHL), using the MeSH terms [obesity, inflammation, disease management, C-reactive
protein (CRP)] is presented. Based on the above, the aims of this work are to provide
information on the relationship between obesity and circulating levels of CRP, to describe
the basic chemical structure and functions, and to analyze its clinical usefulness in obese
patients. The available scientific evidence justifies the need to include determining the
values of high-sensitivity C-reactive protein (hs-CRP) among clinical screening tests on
obese subjects to evaluate the cardiovascular risk, among other risks.
Keywords: obesity, inflammation, C-reactive protein, clinical relevance, cardiovascu-
lar risk
1. Introduction
The rising prevalence of overweight and obesity in the world has been described as a global
pandemic at all stages of life worldwide [1]. Overweight and obesity are defined as abnormal
or excessive fat accumulation that may impair health with serious health complications and
increases the risks of morbidity and the prevalence of several health complications, such as
type-2  diabetes,  hypertension,  atherosclerosis,  dyslipidemia,  prothrombotic  state,  insulin
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resistance, cardiovascular disease, metabolic syndrome, and various types of cancers [2]. A
complex interaction between the environmental factors, genetic predisposition, and human
behavior is the cause of the current obesity pandemic [3]. Obesity has been linked strongly with
metabolic abnormalities including increased blood pressure [4], increased blood sugar [5], and
lipid  profile  abnormalities  [6].  Furthermore,  obesity  has  been  predisposed  to  metabolic
abnormalities via inflammatory process [7].  In the state of obesity,  the pro-inflammatory
adipokines, derived from adipose tissue, are overexpressed, increased production, and secretion
of inflammatory mediators: interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) [8, 9].
The  increased  circulatory  levels  of  inflammatory  mediators  particularly  IL-6  have  been
associated with  hepatocyte  stimulation to  synthesize  and produce a  low-grade systemic
inflammation marker C-reactive protein (CRP) [8]. This protein was discovered in 1930 by Tillet
and Francis, being insulated in the serum of patients with acute inflammatory processes. Upon
its discovery, it was thought that C-reactive protein levels could be a pathogenic secretion for
its high levels in patients with multiple pathologies. Finally, the discovery of its synthesis and
secretion in the liver closed this discussion [10]. Currently, PCR serum represents an effective
clinical indicator of infectious and inflammatory processes in the body, and therefore, it can be
used to determine the risk of heart disease and to predict metabolic syndrome and diabetes
mellitus [11]. In this sense, the systemic inflammation represented by increased level of high-
sensitivity CRP (hs-CRP) has been classified as a characteristic feature and an essential cause of
many illness conditions including metabolic syndrome [12], atherosclerosis [13], coronary heart
disease [14], and cancers [15]. Based on the above, the aims of this work were to provide
information on the relationship between obesity and circulating levels of CRP, to describe the
basic chemical structure and functions, and to analyze its clinical usefulness in obese patients.
2. Overall structure
CRP is a protein of the pentraxins group, which is distinguished by its conformation in the
space, presenting pentameric form of annular disc (see Figure 1). Structurally, it is composed
of five identical subunits unglycosylated and linked by noncovalent bonds that depend of
calcium binding to exert their action [16]. From a functional perspective, the active forms of
PCR are the pentameric or native structure (p-n-PCR or PCR) and the monomeric isoform (m-
PCR). This latter is formed by a dissociation process of the p-PCR. The monomeric isoform
may appear linked to membranes or free in plasma, changing their functions in each case [17].
The pentameric isoform has two faces, one with ability to adhere to the phosphatidylcholine
in the presence of calcium ions [18], while the other presents adhesion sites for complement
component C1q and Fc receptors. The existence of five subunits with capacity to bind together
phosphatidylcholine determines its high avidity for phosphatidylcholine [18]. This interaction
occurs during the identification of microorganisms such as bacteria, fungi, and parasites
showing phosphatidylcholine in their membrane [19]. Once identified pathogens, adherence
to C1q occurs on the other side of the pentamer, activating partially the complement pathway
and adhering to factor H [17]. This mechanism is a first defensive barrier in our organism
against certain pathogens.
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Figure 1. Crystal structure of C-reactive protein complexed with phosphocholine from Thompson et al. [50].
3. Functions and clinical significance in obese subjects
CRP is synthesized in hepatocytes in response to stimulation of interleukin 6 (IL-6) [20], be-
ing their serum concentrations higher among obese subjects [21]. It is an acute phase reac-
tant protein whose plasma levels are elevated rapidly during a tissue damage or aggression
and according to the intensity, reaching its peak in 24–48 h. This increase is due to an in-
crease in the plasma concentration of IL-6, which is produced by macrophages [22], endo-
thelial cells, T cells, and adipocytes [23]. When the inflammatory process ceases, within a
period of 3–7 days, the CRP returns to normal values.
PCR is deposited in anatomical locations in which inflammatory processes occur, as in the
intima of arteries [24]. In this location, PCR could participate in LDL capture by macrophages
in atherosclerotic plaque and thus be related to the development of atherosclerosis [25, 26].
Also, it is known that CRP directly induces the production of other inflammatory cells and
decreases the expression of nitric oxide synthase [27], participating actively in the atherogenic
process. The first evidence of the relationship between circulating CRP levels and the devel-
opment of coronary artery disease were published in 1954, showing an elevated CRP levels in
patients with acute myocardial infarction [28]. However, it will be during the decade of the
nineties when studies show the independent prognostic value of CRP in primary and secon-
dary prevention of coronary artery disease [29, 30]. Currently, by the ultrasensitive method
[31], it can be detected levels of hs-CRP required to the prediction of cardiovascular risk [32].
Based on this method, the American Heart Association (AHA) [33] recommends the following
ranges for predicting cardiovascular risk: <1.0 mg/L low risk, 1.1–3.0 mg/L moderate risk, and
3.1–10.0 mg/L high risk. hs-CRP values in the above ranges have shown sensitivity and
specificity for early detection of vascular events, not just in coronary arteries, also in the
peripheral circulation and brain in obese subjects [34]. Thus, in the study by Jager et al. [35] on
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a population of 2484 individuals, researchers concluded that CRP was an important predictive
value for cardiovascular mortality, especially in association with other risk factors such as
obesity. Other recent studies have shown a direct association between elevated plasma levels
of hs-CRP and the occurrence of cardiovascular accidents, both in individuals without
cardiovascular disease [36, 37], and in individuals with previous cardiovascular disease [38].
In this sense, hs-CRP has demonstrated to be a sensitive and specific marker for early
identification of individuals with cardiovascular risk, especially among obese subjects [39]. On
the other hand, prospective studies show that CRP levels in the general population and
especially in obese subjects is a strong predictor of future coronary events, stroke, peripheral
artery disease, congestive heart failure, and cardiovascular mortality in general [40], with a
continuous gradient of cardiovascular risk over the whole of their serum levels. In addition,
serum levels of CRP may be an indicator of subclinical atherosclerosis, correlating its concen-
tration with intima-media thickness [41] and with the calcification degree of the coronary
arteries [42]. Pande et al. [43], in their study with a population of 3000 patients, described higher
levels of CRP in patients with peripheral arterial disease. Ridker et al. [44], from a population
greater than 13,000 subjects and assessing different inflammatory markers, including CRP, also
found a statistically significant correlation between CRP levels and the risk of peripheral
arterial disease. In addition, in a five-year follow-up in a small cohort of 150 patients, the
authors conclude that those subjects who developed peripheral artery disease had higher
average CRP values during the monitoring period. In this sense, Vainas et al. [45], in a sample
greater than 300 patients with peripheral arterial disease, they conclude that the severity of
peripheral arterial disease was correlated with serum CRP levels.
In the recent study, Gaillard et al. [46] were studied 1116 pregnant women with obesity. The
study was developed during the second trimester of pregnancy and evaluated the serum levels
of CRP in the mothers and fetus’s fat mass. The authors concluded that higher second-trimester
maternal CRP level was associated with higher mid-childhood overall and central adiposity.
Other studies have shown that the obesity is a negative prognostic factor after diagnosis of
breast cancer [47]. There are evidences that propose a greater amount of adipose tissue will
increase the susceptibility of the patients to metastasis development [48]. Several mechanisms
have been proposed to explain the adverse effect of obesity on survival among women with
breast cancer, including alteration in cytokines profiles such as CRP [49]. In this sense,
alteration in acute phase proteins such us CRP in obese patients may exaggerate the inflam-
mation status [47]. Owing to the fact that the inflammation has the potential to prone the
patients toward later distant metastasis, it is necessary to regulate and control the levels of CRP
among other cytokines. Nevertheless, the exact mechanisms in which obesity and CRP levels
may influence breast cancer are not well known and need more research for its clarifying [47].
4. Conclusions
In conclusion, the available scientific evidence justifies the need to include determining the
values of hs-CRP among clinical screening tests on obese subjects to evaluate the cardiovas-
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cular risk, among other risks. CRP is an important clinical parameter in the early detection of
atherosclerotic disease and thus for the prevention of cardiovascular disease in people with
obesity. Its possible influence as an inflammation marker in the prognosis of cancer patients is
another important aspect that needs further study. However, even considering the scientific
evidence, new prospective studies are necessary with larger populations to acquire solid and
extrapolable results to citizenship.
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